Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 57Carcinoma, Hepatocellular 45Colorectal Neoplasms 18Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Esophageal Neoplasms 9Advanced Gastric Cancer 9Biliary Tract Neoplasms 8Pancreatic Neoplasms 6Liver Neoplasms 5Neoplasms 3Neoplasm Metastasis 3Gastrointestinal Neoplasms 3Gastric Adenocarcinoma 3Digestive System Neoplasms 3Recurrence 2Metastatic Gastric Adenocarcinoma 2Locally Advanced Gastric Cancer 2Gastrointestinal Stromal Tumors 2Advanced Esophagus Cancer 2Uterine Cervical Neoplasms 1Stomach Diseases 1Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence 1Peritoneal Metastases From Gastric Cancer 1Ovarian Neoplasms 1Locally Advanced or Metastatic Gastric Adenocarcinoma 1Intestinal Neoplasms 1Immunotherapy Gastrict Cancer 1Immunotherapy 1Hepatic Metastasis of Colorectal Cancer 1

Interventions

camrelizumab 2apatinib 2Ramucirumab 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Fluorouracil 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Gastric Adenocarcinoma × apatinib × Gastrointestinal × Clear all
NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Unknown
68 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡